Gestational diabetes mellitus (GDM) is any degree of glucose intolerance with onset or first recognition during pregnancy.
Hyperglycemia in pregnancy may be suggested by the presence of glycosuria, a fetus that is large for date, or polyhydramnios.
Overt diabetes mellitus may be found in women presenting with risk factors for type 2 diabetes during the first prenatal visit (before 13 weeks of gestation).
Women who conceive singleton pregnancies following assisted reproductive technology (ART) may have a higher risk of developing gestational diabetes than those who conceive spontaneously, according to results of a systematic review and meta-analysis presented at EASD 2019.
Gestational diabetes and abnormal glucose levels in pregnancy, as determined with an oral glucose challenge test (OGCT) at 24–28 weeks gestation, could signal a future risk of cardiovascular disease (CVD)*, according to a recent study.
Metformin continues to protect high-risk individuals from developing type 2 diabetes (T2D) over 15 years, especially among those with higher glycaemic status at baseline and women reporting a history of gestational diabetes mellitus (GDM), according to long-term results from DPP/DPPOS*.
Eating vegetable and protein before carbohydrate attenuated postprandial glucose response in healthy Asian adults, according to the PATTERN* study, suggesting that behavioural change in eating sequence may be a potential strategy for modulating glycaemic response.
The cardiovascular (CV) benefits of the SGLT2* inhibitor dapagliflozin extend across a broad spectrum of patients with type 2 diabetes (T2D) and high CV risk, in particular those with heart failure with reduced ejection fraction (HFrEF), reports a subanalysis of the DECLARE-TIMI 58 trial presented at ACC.19 Annual Scientific Session.
Use of the feminizing hormone therapy medroxyprogesterone acetate (MPA) results in minimal side effects, unchanged oestradiol levels and a decline in testosterone in a cohort of transwomen, a study has found.